The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AIMD | +5.01% | -96.02% | -47.49% | -100% |
| S&P | +12.57% | +87.93% | +13.44% | +917% |
Ainos, Inc. is a diversified medtech company, which engages in the development of medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. Its Medtech Solutions include COVID-19 Antigen Rapid Test Kit, VOC POCT – Ainos Flora, VOC POCT – Ainos Pen, VOC POCT – CHS430, Very Low-Dose Oral Interferon Alpha, and Synthetic RNA. The company was founded in June 1984 and is headquartered in San Diego, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$1.19M | -4591.8% |
| Gross Margin | -25529.62% | 0.0% |
| Market Cap | $12.08M | 141.6% |
| Market Cap / Employee | $0.27M | 0.0% |
| Employees | 44 | -4.3% |
| Net Income | -$4.08M | -27.9% |
| EBITDA | -$2.55M | -37.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.22M | -84.7% |
| Accounts Receivable | $0.00M | 1977.8% |
| Inventory | 0.2 | -3.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $11.00M | 22.2% |
| Short Term Debt | $0.00M | -100.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -52.89% | -8.6% |
| Return On Invested Capital | -2.28% | -214.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.34M | 32.2% |
| Operating Free Cash Flow | -$1.35M | 31.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.37 | 0.45 | 0.64 | 1.06 | 378.90% |
| Price to Sales | 132.94 | 339.37 | 73.37 | 105.22 | 29.19% |
| Price to Tangible Book Value | -3.33 | -4.59 | -4.60 | -1.02 | -81.65% |
| Enterprise Value to EBITDA | -6.85 | -4.40 | -8.64 | -8.40 | 39.07% |
| Return on Equity | -70.6% | -74.4% | -82.9% | -97.8% | 62.18% |
| Total Debt | $12.27M | $12.00M | $12.00M | $11.00M | -20.85% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
